Search Results – Inserm Transfert

Our Technology Offers

Welcome to our Technology Offers website

You want access to an innovative offer which is based on the excellence of Inserm, the leading academic research and clinical institute dedicated to human health in Europe? Find out our technologies offers of patents and research tools: here is a sample of our patents.

BIO21413-T1

Drug Field of development:

Oncology Therapy Area:

Method Type of patent:

Methods and composition to identify and treat subjects resisting to

The present invention relates to a method for treating a subject suffering from a cancer comprising a step of administering said subject with a […]

BIO17261-T1

Drug Field of development:

Oncology Therapy Area:

Method Type of patent:

A checkpoint kinase 1 inhibitor sensitises cancer cells to

The present invention relates to the field of cancer treatment. In this study, the inventors sought to investigate whether this antiproliferative […]

BIO14138-T1

Drug Field of development:

Oncology Therapy Area:

Product Type of patent:

Anti-cathepsin d human antibody for triple negative breast cancer

Inventors have generated two human anti-cath-D scFv fragments cloned in the human IgG1 ??format (F1 and E2) that efficiently bind to human and mouse […]

BIO21413-D1

Biomarker Field of development:

Oncology Therapy Area:

Methods and composition to identify and treat subjects resisting to

The present invention relates to a method for treating a subject suffering from a cancer comprising a step of administering said subject with a […]

BIO20332-D1

Biomarker Field of development:

Oncology Therapy Area:

Method Type of patent:

Methods for improving the efficacy of hdac inhibitor therapy and

Investigating the impact of Tau protein expression in cancer cell lines, Inventors have demonstrated that the Tau expression is associated with an […]

BIO21444-D1

Biomarker Field of development:

Oncology Therapy Area:

Target Type of patent:

Methods and compositions for treating triple negative breast cancer

Inventors analyzed the prognostic value of tumor and stromal-derived SPARC in a large series that included 148 non-metastatic TNBC patients with a […]

147

56

310

46

Our Technology Offers

Methods and composition to identify and treat subjects resisting to

A checkpoint kinase 1 inhibitor sensitises cancer cells to

Anti-cathepsin d human antibody for triple negative breast cancer

Methods and composition to identify and treat subjects resisting to

Methods for improving the efficacy of hdac inhibitor therapy and

Methods and compositions for treating triple negative breast cancer

You might also be interested in

Novel melanoma antigens

Nanobody against ela2a to treat inflammatory bowel

Transoesophageal device using high intensity

Recombinant flagellin for preventing and treating

Methods for expanding a population of alveolar

Use of il-36 inhibitors for the treatment of

Medical device for olfactory stimulation

Antigenic peptides deriving from urocortin 3 and

Pyk2-based gene therapy gene therapy attenuates

Methods and composition to identify and treat

Anti-neurotensin mab for the treatment of cancer

Lipid antisens oligonucleotide targeting fxyd2 as